Abstract
In the Institute for Pulmonary Diseases of Vojvodina application of chemotherapy is implemented according to the latest recommendations of the National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) and the recommendations of the national Ministry of Health Guidelines Republic of Serbia. According to these recommendations as adjuvant chemotherapy for Non Small Cell Lung Cancer (NSCLC) cisplatin doublets are used (etoposide/vinorelbine, gemcitabine) or paclitaxel/carboplatin. For the first-line treatment in advanced and metastatic NSCLC standard regimen is cisplatin or carboplatin in combination with the gemcitabine/etoposide/vinorelbine or paclitaxel. In EGFR mutated patients gefitinib or erlotinib are the first options. In some clinical studies bevacizumab is used in the first line as well as erlotinib single. For the second-line treatment docetaxel/cisplatin is in standard use and erlotinib single in patients who had haematological side effects in the first line chemotherapy. Pemetrexed in combination with cisplatin is standard treatment for malignant pleural mesothelioma. In SCLC patients cisplatin/etoposide is first line treatment. Depends on disease-free survival as the second-line chemotherapy cisplatin/etoposide or topotecan are protocols could be applied. Prophylactic cranial irradiation is recommended for patients with the limited and extensive stage SCLC with any response rate to therapy. We participate, as the other institutions, in some clinical studies to the appropriate procedures for implementation.